110 results about "Antibody level" patented technology

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.

The invention discloses an antigen fusion protein and application thereof in preparation of a live vaccine for preventing infectious bursal disease. Specifically disclosed are antigen fusion proteins comprising a VP2 protein, a trimer tag, and a C3d protein. The invention also discloses recombinant Eimeria heap constructed by using the antigen fusion protein and application of the recombinant Eimeria heap in preparation of IBDV live vaccines. The oocyst of the recombinant Eimeria heap can effectively induce humoral immune response aiming at IBDV as a vaccine active ingredient, the level of an induced antibody is obviously higher than that of an insect strain expressed by a single VP2 antigen, viruses can be more effectively neutralized, the immune protection efficacy is improved, the safety is high, and the oocyst has the potential of serving as a live vector genetic engineering vaccine. The IBDV live vaccine can be orally taken through drinking water or feed, vaccination is simple, large-scale immunization of chicken flocks can be achieved, and the IBDV live vaccine is economical and efficient and has a wide prospect of being applied to prevention and control of the IBDV of the chicken flocks.

The invention provides a solid-phase agglutination detection test paper card and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a cell carrying a specific antigen or a conjugate formed by coupling the specific antigen and an inert carrier, and the granular antigen can be colored or has a luminescence property in various modes. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.

The invention relates to the field of immunology, and discloses a polypeptide and a kit for distinguishing bovine and sheep brucella natural infection from a vaccine immune antibody. Polypeptides as shown in SEQ ID NO: 1 and SEQ ID NO: 2 are artificially synthesized and used as antigens to coat an elisa plate and a nitrocellulose membrane, and according to response characteristics of antibody level, identification and detection of natural infection and vaccine immunity of cattle and sheep populations are realized. The peptide fragment and the detection kit provided by the invention can make up the blank of identifying bovine and sheep brucella natural infection and immune antibodies. The method solves the problem that the antibody induced by the attenuated live vaccine and the naturally infected antibody are difficult to distinguish, provides a scientific basis for quarantine and purification of Brucella, and provides a technical guarantee for preventing human diseases and animals, advancing the mouth and protecting the body health of people.

The invention provides a solid-phase agglutination detection test paper card directly marked by antigens and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a conjugate formed by coupling a specific antigen and an inert carrier, the specific antigen is not a protein, and the specific antigen is specifically combined with an antibody to be detected. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.

The application provides a PDCoV virus mRNA vaccine which can be self-cleaved and expresses multiple virus structure proteins and a preparation method thereof, the vaccine comprises mRNA for expressing PDCoV virus S, M and N proteins, and LNP for encapsulating the mRNA, denoted as SMN-mRNA-LNP. The application firstly proposes a PDCoV mRNA vaccine strategy based on S, M and N combination, connects three structure proteins of PDCoV S, M and N by using a self-cleaving peptide P2A, mutates the S protein with double proline, enables a single mRNA to express multiple PDCoV antigens, and utilizes the neutralizing antibody induction ability of the S protein, the immune regulation function of the M protein and the cell immune activation characteristics of the N protein to construct a multi-level defense system. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea for developing a broad-spectrum and high-efficiency PDCoV vaccine is provided, and practical basis for research and development of a coronavirus multi-antigen mRNA vaccine is provided.

The invention belongs to the technical field of biological medicines, and particularly relates to application and a method of PHF20 in preparation of a medicine for treating systemic lupus erythematosus and the medicine. The invention discloses an application of PHF20 in treatment of systemic lupus erythematosus, a lentivirus with murine PHF20 is selected as a gene therapy tool, an R848 induced lupus mouse model is taken as an experimental subject for gene therapy, and results show that injection of the overexpressed PHF20 lentivirus in a lupus mouse body has the following effects: (1) spleen swelling is improved, and spleen index is significantly reduced; (2) reducing urine protein, urea nitrogen level, anti-dsDNA antibody level and IgG antibody level of the model mouse; and (3) the pathological damage to the kidney of the model mouse is relieved. The research results show that the PHF20 serving as the target provides important reference value for potential application prospects in systemic lupus erythematosus gene therapy and even autoimmune disease gene therapy.

AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The application discloses a preparation method of a tetravalent influenza virus split vaccine and belongs to the technical field of vaccines. The preparation method of the tetravalent influenza virus split vaccine comprises the following steps: pre-incubation of a chicken embryo, pre-embryo inspection, virus inoculation and culture, post-embryo inspection, cold embryo, virus harvesting, ultrafiltration clarification, zone centrifugation, desugaring, chromatography, virus splitting, virus inactivation, ultrafiltration liquid replacement, sterilization filtration and preparation of a tetravalent influenza virus split vaccine product. Compared with the prior art, the technical means adopted in the application effectively reduces the content of free formaldehyde and improves the antibody level of the vaccine.

The application belongs to the technical field of biotechnology, and discloses a nano antibody targeting B cell BCMA and application thereof. The amino acid sequences of the complementarity determining regions CDR1-CDR3 of the nano antibody are selected from SEQ ID NO. 1-12. The nano antibody provided by the application can specifically bind to B cells in human blood, especially activated plasma cells, so as to eliminate B cells producing pathological antibodies. Compared with traditional antibodies, the nano antibody provided by the application has a smaller molecular weight, high stability, low cost, easy expression and high expression amount, and is suitable for large-scale production. The nano antibody is combined with a solid-phase carrier in the application, so that B cells in blood can be targeted and eliminated, the number of B cells in blood of patients can be reduced in a short time, and the antibody level can be reduced, thereby improving the quality of life, reducing complications, and providing a new treatment option for patients who are ineffective or intolerant to traditional treatment.

The invention relates to a high-affinity mouse anti-carp IgM (Immunoglobulin M) monoclonal antibody, a hybridoma cell strain and application of the high-affinity mouse anti-carp IgM monoclonal antibody and the hybridoma cell strain. The mouse anti-carp IgM monoclonal antibody is secreted by the hybridoma cell strain CcM-12A12G11C9C7 with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C2024236. The mouse anti-carp IgM monoclonal antibody can be used for Western blot and ELISA specific detection of IgM in a carp secretion form, and can be used for flow cytometry identification of carp IgM + B cells. The monoclonal antibody is good in specificity and high in sensitivity, can be used for structural analysis, immune response level detection and the like of carp IgM, and lays a foundation for in-depth study of a carp immune system and establishment of a vaccine immune effect evaluation method taking the antibody level as an index.

The application discloses a chicken Newcastle disease, avian influenza and chicken infectious rhinitis triple inactivated vaccine and preparation and application thereof, and relates to the technical field of bioengineering. The application discloses a preparation method and application of a chicken Newcastle disease, avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine. The preparation method comprises the following steps: constructing and expressing a serum B paracolon avian bacillus subunit protein expression strain; and preparing the chicken Newcastle disease, H9 subtype avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine at a certain ratio. The triple inactivated vaccine has good safety, can be used for the prevention of chicken Newcastle disease, H9 subtype avian influenza and A, B and C three serotypes paracolon avian bacillus diseases in a laying hen group, and does not cause the decrease of the laying rate after immunization. Meanwhile, the paracolon avian bacillus subunit protein can improve the antibody level of the Newcastle disease and the H9 avian influenza, and the protection of the vaccine on the A, B and C three serotypes paracolon avian bacillus can reach 100%.

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a compound protein preparation for preventing and treating avian influenza and a preparation method thereof. The compound protein preparation is prepared from the following raw materials in parts by weight: 5 to 10 parts of immune globulin, 15 to 19 parts of radix puerariae, 10 to 15 parts of buchnera macrocarpa, 8 to 12 parts of dendranthema morifolium, 7 to 10 parts of honeysuckle flower, 3 to 10 parts of radix astragali seu hedysari, 2 to 8 parts of echinacea purpurea, 1 to 7 parts of semen cuscutae and 2 to 5 parts of liquorice root. By taking the compound protein preparation for preventing and treating the avian influenza, clinical symptoms caused by the avian influenza can be effectively relieved, and the health level of animals is improved; the vaccine-induced immune response can be effectively enhanced, so that the avian influenza antibody level of animals is improved, the avian influenza is effectively prevented and treated, and the vaccine has a wide application prospect.

This invention belongs to the field of molecular marker technology, specifically relating to SNP molecular markers, primers, and applications of the PRRX2 gene associated with African swine fever virus (ASFV) antibody levels. The SNP molecular marker is located at 143 bp of exon 3 of the porcine PRRX2 gene (genotype XM_005654574.2), exhibiting T / C polymorphism. The nucleotide sequence of the SNP molecular marker is shown in SEQ ID NO.3. The molecular marker provided by this invention is closely associated with ASFV antibody levels in pigs. Compared to pigs with the TC / CC genotype at this locus, pigs with the TT genotype have higher ASFV antibody levels in their serum. This molecular marker can be applied to breed high-quality breeding pigs resistant to ASFV, thereby effectively improving the economic benefits of pig farming.

The application provides a monoclonal antibody specifically binding to Brucella LPS, the monoclonal antibody having three light chain complementarity determining regions and three heavy chain complementarity determining regions; the amino acid sequences of the light chain complementarity determining regions are respectively the 24th to 40th amino acids in the sequence table SEQ ID NO. 1, the 56th to 62nd amino acids in the sequence table SEQ ID NO. 1 and the 95th to 102nd amino acids in the sequence table SEQ ID NO. 1; the amino acid sequences of the heavy chain complementarity determining regions are respectively the 31st to 37th amino acids in the sequence table SEQ ID NO. 3, the 52nd to 67th amino acids in the sequence table SEQ ID NO. 3 and the 100th to 113th amino acids in the sequence table SEQ ID NO. 3. The application further discloses a preparation method of the monoclonal antibody and application of the monoclonal antibody in quantitative detection of Brucella LPS antibody level.

The application discloses a polycarbonate polymer, a preparation method and application, and relates to the biomedical field. The polycarbonate polymer synthesized by the application has simple synthesis and definite structure, can induce higher neutralizing antibody level when used as a rabies vaccine nano adjuvant, and can carry and transport antigens to corresponding immune cells to fully exert the immune effect. The experimental results show that the polycarbonate polymer provided by the application can significantly improve the antibody level in the body of a mouse, enhance the antigen cross-presentation ability, effectively enhance the immune response intensity, and has a synergistic effect after the polycarbonate polymer, LTB protein and antigen are combined.

The invention relates to a multivalent Congo hemorrhagic fever mRNA (messenger ribonucleic acid) vaccine which is characterized by sequentially comprising a coding sequence of GP38 protein of a Congo hemorrhagic fever virus, a coding sequence of GC protein and a coding sequence of NP protein from 5'to 3 ', preferably, the coding sequence of the GP38 protein, the coding sequence of the GC protein and the coding sequence of the NP protein are connected in series through a flexible joint and / or a self-shearing joint; optionally, the GP38 protein, the GC protein and the NP protein are from a Crimean Congo hemorrhagic fever virus IbAr10200 strain. Researches show that after mice are immunized with the mRNA vaccine for co-expressing the three antigen proteins of the Crimean Congo hemorrhagic fever GP38, GC and NP through series connection of a flexible joint and a self-cleavage joint, a good antibody level can be generated, and the mice are protected from lethal infection of a Crimean Congo hemorrhagic fever YL16070 strain.

Provided herein are methods for administering hepatitis B virus surface antigen (HBsAg) to a subject suffering from chronic hepatitis B to differentiate between responder subjects and non-responder subjects that the administration of HBsAg results in an increased response to HBV antibody levels, and treating chronic hepatitis B in responder subjects using HBV therapy. Also provided are methods of excluding unresponded subjects outside a clinical study.

The application provides a construction method and application of a Toxoplasma gondii attenuated strain PruDelta pp2a-c and belongs to the technical field of biological medicine. The TgPP2A-C gene is knocked out to obtain a TgPP2A-C gene deletion Toxoplasma gondii attenuated strain. After the gene is deleted, a large number of starch granules are aggregated between the bodies of the Toxoplasma gondii, and the Toxoplasma gondii loses the ability to form cysts. The in-vitro proliferation speed and pathogenicity of the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain are significantly reduced compared with those of a wild strain. After being infected with the TgPP2A-C gene deletion strain, a mouse does not get ill or die, and no cysts are detected in the brain tissue of the mouse, so the TgPP2A-C gene deletion strain has high safety to a host. After a mouse is immunized with the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain, the antibody level of the mouse is significantly improved, and the mouse can provide significant immunoprotection efficacy against high-dose Toxoplasma gondii RH tachyzoite and Pru cyst re-infection, and can prevent re-infection of Toxoplasma gondii.

The invention provides a bivalent bovine viral diarrhea virus antigen protein composition, a subunit vaccine as well as a preparation method and application of the bivalent bovine viral diarrhea virus antigen protein composition and the subunit vaccine, and belongs to the technical field of genetic engineering vaccines. The bivalent bovine viral diarrhea virus antigen protein composition is prepared from a recombinant protein kozak-MLTsp-BVDV1-E2-His and a recombinant protein kozak-IgKsp-BVDV2-E2-His, the amino acid sequence of the recombinant protein kozak-MLTsp-BVDV1-E2-His is as shown in SEQ ID NO.16, and the amino acid sequence of the recombinant protein kozak-IgKsp-BVDV2-E2-His is as shown in SEQ ID NO.18. The invention further discloses a preparation method of the bivalent bovine viral diarrhea virus antigen protein composition. According to the invention, efficient expression of BVDV-1 and BVDV-2 E2 proteins is realized, high-purity E2 proteins are obtained, the safety and effectiveness of vaccines are ensured, and the antibody level of the vaccines is improved.

The invention discloses application of CpG ODN in preparation of a medicine for regulating animal immune cell activity, and relates to the technical field of animal vaccines. In the invention, the regulation of the animal immune cell activity is to promote the immune response reaction of immune cells; the step of promoting the immune response reaction of the immune cells comprises the step of promoting the immune cells to generate interferon. The CpG ODN provided by the invention can well and specifically stimulate immune cells of animals, especially pigs to release cytokines and promote the animals to generate rapid and strong immune response to immunogens; when being applied to an animal vaccine, the vaccine can stimulate animals to generate a higher antibody level in a shorter time, and can maintain the high-level antibody for a long time, and the immunogenicity of the vaccine is remarkably improved.

The invention belongs to the technical field of kit preparation, and particularly relates to preparation and application of a pertussis acute infection detection test strip based on double-T-line immunochromatography. The amino acid sequence of the recombinant protein provided by the invention is as shown in SEQ ID NO. 1. The recombinant protein is used as an antigen to prepare a double-T-line test strip for detecting the pertussis IgG antibody, and the test strip is extremely simple and convenient to operate, rapid in detection and visual and reliable in result interpretation, has excellent sensitivity, specificity and stability, can realize semi-quantitative detection of the pertussis IgG antibody, and can be used for detecting the pertussis IgG antibody. The pertussis IgG antibody detection method solves the problems that an existing pertussis IgG antibody detection method is complex in operation, long in consumed time and high in cost, whether the antibody level is in an immune protection state or an acute infection state can be preliminarily judged according to the color development condition of a detection line, and powerful support is provided for clinical pertussis infection diagnosis and disease prevention and control.

The application discloses a bovine coronavirus virus-like particle, a preparation method and application, and the bovine coronavirus virus-like particle is assembled after co-infection of five kinds of recombinant baculoviruses capable of stably secreting bovine coronavirus E, M, N, S and HE proteins, and contains complete bovine coronavirus E, M, N, S and HE proteins, and BCoV VLPs similar to natural BCoV virus particles in morphology and size are constructed; after bovine coronavirus virus-like particles obtained by the application are used for immunizing mice and calves, high-titer antibody levels can be generated, and cellular immunity of the body can be stimulated.

B-cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells. In certain embodiments, the bispecific antibodies of the present invention reduce alloantibody levels and / or reduce calculated panel reactive antibody levels to facilitate solid organ transplantation and / or improve long term graft survival and / or function.

The application discloses application of citrullinated galectin-1 polypeptide in preparation of a rheumatoid arthritis diagnosis product, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated galectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE; the product is used for detecting the content of anti-citrullinated galectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is significantly different between RA patients, normal healthy people and other common rheumatic immune disease patients who are easily confused with rheumatoid arthritis. The product has good sensitivity to common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnosis value for the diagnosis of RA.

The present disclosure relates generally to methods of treating lupus nephritis in a subject in need thereof. The method comprises determining that the subject has at least one of the following characteristics: an elevated C4x level; an elevated C4x / C4 ratio, a reduced C4 level; an elevated C1sC1 inhibitor level; an elevated C1sC1 inhibitor / Cis ratio; a reduced C1s level; an elevated C2b level; an elevated C2b / C2 ratio; a reduced C2 level; or an elevated Pathogenic Anti-C1q Antibody 1 (PACA1) and / or Pathogenic Anti-C1q Antibody 3 (PACA3) level; wherein C4x is selected from C4a, C4b and C4d, and administering to the subject an inhibitor of the classical complement pathway.

The invention discloses an anti-tilapia mossambica IgM monoclonal antibody, a hybridoma cell strain and application thereof. The CDR sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.1-3, and the CDR sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.4-6; the monoclonal antibody can be secreted by a hybridoma cell strain with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C2023153. The monoclonal antibody provided by the invention can be used for Western blot and ELISA specific detection of tilapia mossambica secretion form IgM, can be used for flow cytometry identification of tilapia mossambica IgM + B cells, has the characteristics of good specificity, high sensitivity, strong affinity and the like, can be used for structural analysis, immune response level detection and the like of tilapia mossambica IgM, and can be used for preparing a tilapia mossambica IgM immunoassay kit. And a foundation is laid for deep research of a tilapia immune system and establishment of a tilapia vaccine immune effect evaluation method taking the antibody level as an index.

The invention belongs to the technical field of genetic engineering, and particularly relates to a chimeric virus-like particle vaccine of feline coronavirus and feline panleucopenia virus and application of the chimeric virus-like particle vaccine. The invention provides chimeric virus-like particles of feline coronavirus and feline panleucopenia virus. The chimeric virus-like particles contain feline coronavirus type I S protein and feline panleucopenia virus VP2 protein. The invention also provides a preparation method and application of the chimeric virus-like particle. After the vaccine prepared from the chimeric virus-like particles is used for immunizing mice and cats, a high-titer antibody level can be generated, and the organism is stimulated to generate cellular immunity; the immunized cat can effectively resist invasion of cat coronavirus and cat panleucopenia virus. The chimeric virus-like particle has good immunogenicity and can be used for preventing and controlling cat infectious diseases.